Advances with phospholipid signalling as a target for anticancer drug development

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Phosphatidylinositol-3-kinases (PtdIns-3-kinase) regulate cell replication.
• The mammalian p110/p85 PtdIns-3-kinase is implicated in growth factor and oncogene signaling pathways.
• This enzyme is a potential target for novel anticancer therapeutics.

Purpose of the Study:

• To review inhibitors of PtdIns-3-kinase for anticancer drug development.
• To highlight the efficacy of wortmannin and other inhibitors against cancer cell growth.
• To explore novel myo-inositol analogues as potential antimetabolites in the PtdIns-3-kinase pathway.

Main Methods:

• Review of existing literature on PtdIns-3-kinase inhibitors.
• Analysis of data on wortmannin's potency (IC50 4 nM) and in vivo antitumor activity.
• Synthesis and evaluation of D-3-deoxy-3-substituted myo-inositol analogues and PtdIns analogues.

Main Results:

• Wortmannin is a potent PtdIns-3-kinase inhibitor, demonstrating efficacy against tumor xenografts.
• Halogenated quinones also inhibit cancer cell growth and exhibit in vivo antitumor activity.
• Synthesized myo-inositol analogues act as antimetabolites, inhibiting cancer cell proliferation.

Conclusions:

• PtdIns-3-kinase inhibitors, including wortmannin and halogenated quinones, represent promising anticancer agents.
• Novel myo-inositol analogues offer a potential new class of antimetabolites targeting the PtdIns-3-kinase pathway.
• Targeting PtdIns-3-kinase signaling is a viable strategy for developing new cancer therapies.